Full Circle: Allergan's Revenue Growth Fuels Reinvestment In Sales, R&D
Executive Summary
Allergan generated enough cash flow in the first quarter to justify increased spending to develop and promote new products in 2017 – reinvesting because it can, not necessarily because it has to.
You may also be interested in...
Medical Aesthetics: Key Players In A Largely Untapped Market
Medical aesthetics is a growing, but largely untapped biopharma niche with unique consumer marketing and doctor relationship-building strategies where key players have honed their skills for many years. Allergan's blockbuster Botox dominates, but competitors are gaining ground.
Allergan Focuses On Aesthetics As Sales Dip For Dry Eye Leader Restasis
Allergan's second quarter exceeded expectations and full-year guidance was raised slightly, but while the aesthetics business grew, ophthalmology with a 9.4% Restasis decline was a notable outlier.
2Q Pharma Results Preview: Pfizer, Allergan, Teva, Merck KGaA & Shire
Pfizer will anchor the final week of major biopharma earnings calls, facing the same question as every firm with massive stockpiles of cash: When are you going to spend that money on a transformative M&A deal?